The Business Research Company's kimmtrak Global market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

Immunocore Holdings plc announced its strategic priorities for 2025, focusing on expanding access to its melanoma treatment, KIMMTRAK (tebentafusp), and advancing its clinical pipeline in oncology ...

The Company also highlights the potential of its melanoma franchise building on KIMMTRAK’s performance and reveals details of IMC-U120AI (CD1a x PD1), its first non-HLA restricted candidate.

Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United ...

The Company also highlights the potential of its melanoma franchise building on KIMMTRAK’s performance and reveals details of IMC-U120AI its first non-HLA restricted candidate. This second ...

Cost-effectiveness agency NICE has recommended NHS use of the therapy, called Kimmtrak (tebentafusp), for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal ...

The Business Research Company The Business Research Company’s kimmtrak Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts t ...

"Millions of packages moved away from SurePost and the United States Postal Service and returned to UPS package cars this month, now being sorted and delivered by hardworking UPS Teamsters." ...

but one of the conclusions of the pilot was that a pre-requisite for adoption will be "robust systems in place ensuring that the patient can easily access the package leaflet for their medicine in ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his abdomen after drinking water. It was just a fleeting moment; one he ...

Immunocore Holdings PLC has unveiled its strategic priorities for 2025, including plans to expand access to its Kimmtrak (tebentafusp) drug for metastatic uveal melanoma patients in more countries.

NEW YORK – Immunocore on Friday announced several strategic priorities and pipeline updates including plans to grow the use of Kimmtrak (tebentafusp) in HLA-A*02:01-positive metastatic uveal melanoma.